Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Emory University
- Target Recruit Count
- 32
- Registration Number
- NCT01549431
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01537861
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01496118
- Locations
- 🇺🇸
Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01470196
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01464034
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
- Conditions
- Multiple Myeloma
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT01410500
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT01402284
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Plasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01372540
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT01351623
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
- Conditions
- Peripheral T-cell LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaRecurrent Adult T-cell Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 15
- Registration Number
- NCT01336920
- Locations
- 🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.